C: Financial Instruments with similar economic effect to Qualifying Financial Instrument
Resulting situation after the triggering transaction
Type of financial instrument
Exercise price
Expiration datexvii
Exercise/ Conversion periodxviii
Number of voting rights instrument refers to
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
Expiration
Exercise/
Number of voting
instrument
datexiii
Conversion Periodxiv
rights that may be
acquired if the
instrument is
exercised/ converted.
8. Notified details:
A: Voting rights attached to sharesviii,ix
Class/type of shares
if possible using the ISIN CODE
Situation previous to the triggering transaction
Resulting situation after the triggering transa
Number of Shares
Number of Voting Rights
Number of shares
Number of voting rights
%
Direct
Directxi
Indirectxii
Di
Ordinary Shares
GB00BVGBWW93
331,555,214
331,555,214
330,535,214
RNS Number : 2060V Assura PLC
26 January 2017
For filings with the FCA include the annex For filings with issuer exclude the annex
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:ii
2 Reason for the notification(please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
An acquisition or disposal of qualifying financial instruments which may result in the acquisition shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify): Allotment of new shares
3. Full name of person(s) subject to the notification obligation:iii
Invesco Limited
4. Full name of shareholder(s)
(if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or
reached:v
24 January 2017
6. Date on which issuer notified:
25 January 2017
7. Threshold(s) that is/are crossed or reached:vi, vii
19%
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:xxi
Proxy Voting:
10. Name of the proxy holder:
In
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
The company news service from the London Stock Exchange
END
HOLBFMLTMBBTMFR
Assura plc published this content on 26 January 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 January 2017 09:25:08 UTC.
Original documenthttps://assuraplc.com/wp-content/uploads/sites/2/rns/rns--2017-01-26--09-19-32.pdf
Public permalinkhttp://www.publicnow.com/view/0812523AAD91AD51A3666164750EB5248112CAD8
Assura plc is a United Kingdom-based real estate investment trust (REIT). The Company specializes in the development of, investment in and management of a portfolio of primary care, diagnostic and treatment buildings across the United Kingdom. It develops new buildings, invests in existing buildings, manages portfolios, and ultimately, owns them for the long term. It also designs, builds, invests in, and manages GP surgery, primary care, and community healthcare buildings so the NHS has the places and spaces it needs to deliver more services, tests, and treatments in the community. The Company owns and manages a portfolio of about 612 properties. The Companyâs subsidiaries include Assura (SC1) Ltd, BHE (St James) Ltd, Assura PCP UK Ltd, Metro MRI Ltd, Upton Community Health Care Ltd, Cheltenham Family Health Care Centre Ltd, Upton Medical Ltd, Xantaris Investments (XXI) Ltd, Assura Services Ltd, Assura Primary Care Properties Ltd, Assura Trellech Ltd, and others.